Abstract:Background The word selectivity describes a drug's ability to affect a particular cell population in preference to others. As part of the current state of art in the search for new therapeutic agents, the property of selectivity is a mode of action thought to have a high degree of desirability. Consequently there is a growing activity in this area of research. Selectivity is generally a worthy property in a drug because a drug having high selectivity may have a dramatic effect when there is a single agent that can be targeted against the appropriate molecular-driver involved in the pathogenesis of a disease. An example is chronic myeloid leukemia (CML). CML has a specific chromosomal abnormality, the Philadelphia chromosome, that results in a single gene that produces an abnormal protein Discussion There is a burgeoning understanding of the cellular mechanisms that control the etiology and pathogeneses of diseases. This understanding both enables and motivates the development of drugs that induce a specific action in a selected cell population; i.e., a targeted treatment. Consequently, drugs that can target distinct molecular targets involved in pathologic/pathogenetic processes, or signal-transduction pathways, are being developed. However, in most cases, diseases involve multiple abnormalities. A disease may be associated with more than one dysfunctional protein and these may be out-of-balance with each other. Likewise a drug might strongly target a protein that shares a similar active domain with other proteins. A drug may also target pleiotropic cytokines, or other proteins that have multi-physiological functions. In this way multiple normal cellular pathways can be simultaneously influenced. Long term experience with drugs supposedly designed for only a single target, but which unavoidably involve other functional effects, is uncovering the fact that molecular targeting is not medically flawless. Summary We contend that an ideal drug may be one whose efficacy is based not on the inhibition of a single target, but rather on the rebalancing of the several proteins or events, that contribute to the etiology, pathogeneses, and progression of diseases, i.e., in effect a promiscuous drug. Ideally, if this could be done at minimum drug concentration, side effects could be minimized. Corollaries to this argument are that the growing fervor for researching truly selective drugs may be imprudent when considering the totality of responses; and that the expensive screening techniques used to discover these, may be both medically and financially inefficient.

Investigation of the Relationship Between Topology and Selectivity for Druglike Molecules.

Methods to Profile the Macromolecular Targets of Small Compounds.

Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds

Molecular Topology Analysis of the Differences Between Drugs, Clinical Candidate Compounds, and Bioactive Molecules

Insights into Molecular Basis of Cytochrome P450 Inhibitory Promiscuity of Compounds.

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)

Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

An integrated drug-likeness study for bicyclic privileged structures: from physicochemical properties to in vitro ADME properties

Drug-membrane permeability across chemical space

Accelerating the identification of subtype selective inhibitors via Three-Dimensional Biologically Relevant Spectrum (BRS-3D): The monoamine oxidase subtypes as a case study

Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs.

Drug-likeness Analysis of Traditional Chinese Medicines: 2. Characterization of Scaffold Architectures for Drug-Like Compounds, Non-Drug-like Compounds, and Natural Compounds from Traditional Chinese Medicines.

Molecular Topology for the Discovery of New Broad-Spectrum Antibacterial Drugs

Quantitatively integrating molecular structure and bioactivity profile evidence into drug-target relationship analysis

Aromatic Rings Commonly Used in Medicinal Chemistry: Force Fields Comparison and Interactions With Water Toward the Design of New Chemical Entities

A review on molecular topology: applying graph theory to drug discovery and design

Identification and prediction of promiscuous aggregating inhibitors among known drugs

Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition

Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium

Drug release and solubility properties of two zeolitic metal-organic frameworks influenced by their hydrophobicity/hydrophilicity